89bio
Business Services · California, United States · 70 Employees
View Company Info for Free
About
Headquarters
655 Montgomery St Fl 15, San Francisco, Califor...Phone Number
(415) 432-9270Website
www.89bio.comRevenue
$14.8 MillionStock Symbol
ETNBIndustry
Most Recent Scoops
Who is 89bio
89bio Org Chart
Is 89bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if 89bio had a recent Job posting/layoffs
89bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when 89bio launches new products
Earning: See what the market has to say on 89bio recently announced quarterly report
Check if 89bio has recently received funding, and reach out quickly before it becomes old news!
Check out if 89bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at 89bio
Funding: Get notified immidiatlly once 89bio has new funding data
Recommended Actions
Find VP level buyers at 89bio
Find 2 more new buyers
Compare Similar Companies to 89bio
Compare insights from companies similar to 89bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
89bio
89bio Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
89bio Tech Stack
A closer look at the technologies used by 89bio
Most Recent Scoops
89bio News & Media
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 8:20 AM ET and participate in one-on-one investor me89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
– The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials –89bio to Participate in the UBS Global Healthcare Conference
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings.
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding 89bio
89bio is a clinical-stage biopharma company focused on the development and commercialization of therapies for the treatment of non-alcoholic liver and cardio-metabolic diseases. The company is headquartered in San Francisco with operations in Herzliya, Israel.... Read More